Question Presented (AI Summary)
Whether, in a patent-infringement suit, a court may consider after arising technology to hold that the patent is invalid under § 112(a) of the Patent Act?
Question Presented (OCR Extract)
In a patent case, “after -arising technology” is technology that was not invented until after the patent’s filing. Neither this Court nor the Federal Circuit en banc has addressed the disclosure rules for after -arising technology. One line of Federal Circui t case law holds that when a patentee secures a claim construction that ensnares, as infringing, an accused device that features after -arising technology, the patentee risks invalidating its own patent under 35 U.S.C. § 112(a), which requires a patentee to describe and teach the claimed invention. A contradictory line of Federal Circuit decisions, including the decision below, carves out an exception for after -arising technology. This line holds that “later -existing state of the art … may not be properly considered” in the validity analysis. After -arising technology, that is, may not “reach back and invalidate” a patent. Yet that proposition conflicts with The Incandescent Lamp Patent , 159 U.S. 465 (1895). Edison’s after -arising bamboo -filament technology ex posed the invalidity of Sawyer and Man’s patent for an electric lightbulb . The question presented is: Whether, in a patent -infringement suit, a court may consider after arising technology to hold that the patent is invalid under § 112(a) of the Patent Act?
2025-11-25
Reply of petitioners MSN Pharmaceuticals, Inc., et al. filed. (Distributed)
2025-11-25
Reply of MSN Pharmaceuticals, Inc., et al. submitted.
2025-11-25
DISTRIBUTED for Conference of 12/12/2025.
2025-11-07
Brief of respondent Novartis Pharmaceuticals Corporation in opposition filed.
2025-11-07
Brief of Novartis Pharmaceuticals Corporation in opposition submitted.
2025-10-08
Amicus brief of Biophore Pharma Inc.; Natco Pharma Inc.; and Deva Holding A/S submitted.
2025-10-08
Amicus brief of Public Interest Patent Law Institute submitted.
2025-10-08
Amicus brief of Sigmapharm Laboratories, LLC submitted.
2025-10-08
Amicus brief of Professors Jonathan Masur and Lisa Ouellette submitted.
2025-10-08
Brief amicus curiae of Public Interest Patent Law Institute filed.
2025-10-08
Brief amici curiae of Biophore Pharma Inc., et al. filed.
2025-10-08
Brief amicus curiae of Sigmapharm Laboratories, LLC filed.
2025-10-08
Brief amici curiae of Professors Jonathan Masur, et al. filed.
2025-10-08
Brief amici curiae of Intellectual Property Law Professors filed.
2025-10-08
Brief amici curiae of Biophore Pharma, Inc., et al. filed.
2025-10-08
Brief amici curiae of Professor Jonathan Masur, et al. filed.
2025-10-01
Brief amicus curiae of Unified Patents, LLC filed.
2025-10-01
Amicus brief of Unified Patents, LLC submitted.
2025-09-18
Motion to extend the time to file a response is granted and the time is extended to and including November 7, 2025.
2025-09-17
Motion to extend the time to file a response from October 8, 2025 to November 7, 2025, submitted to The Clerk.
2025-09-17
Motion of Novartis Pharmaceuticals Corporation for an extension of time submitted.
2025-09-08
Response Requested. (Due October 8, 2025)
2025-09-04
Letter from counsel of MSN Pharmaceuticals, Inc., et al. received.
2025-09-04
Letter received from MSN Pharmaceuticals, Inc., et al.
2025-09-04
Letter regarding upcoming Amicus Briefs of MSN Pharmaceuticals, Inc., et al. submitted.
2025-09-03
Brief amicus curiae of Association for Accessible Medicines filed. (Distributed)
2025-09-03
Brief amicus curiae of The Association for Accessible Medicines filed. (Distributed)
2025-09-03
Amicus brief of The Association for Accessible Medicines submitted.
2025-09-03
DISTRIBUTED for Conference of 9/29/2025.
2025-09-02
Waiver of right of respondent Novartis Pharmaceuticals Corporation to respond filed.
2025-08-22
Petition for a writ of certiorari filed. (Response due September 25, 2025)
2025-06-11
Application (24A1215) granted by The Chief Justice extending the time to file until August 22, 2025.
2025-06-06
Application (24A1215) to extend the time to file a petition for a writ of certiorari from June 23, 2025 to August 22, 2025, submitted to The Chief Justice.